GLP-1受体激动剂-话题@MedSci

#GLP-1受体激动剂#

37篇内容 | 4189人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1294046, encodeId=7bb61294046cd, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, objectType=article, longId=220003, objectId=76552200039d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76552200039d, replyNumber=0, likeNumber=156, createdTime=2021-11-10, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76552200039d, moduleTitle=Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76552200039d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294045, encodeId=b884129404542, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, objectType=article, longId=217820, objectId=f24821e820ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f24821e820ef, replyNumber=0, likeNumber=118, createdTime=2021-09-30, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f24821e820ef, moduleTitle=Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f24821e820ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294044, encodeId=794412940441b, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, objectType=article, longId=216263, objectId=a32e21626362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a32e21626362, replyNumber=0, likeNumber=110, createdTime=2021-08-26, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a32e21626362, moduleTitle=Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a32e21626362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294043, encodeId=6e691294043e6, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, objectType=article, longId=213906, objectId=58312139068b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58312139068b, replyNumber=0, likeNumber=153, createdTime=2021-07-09, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58312139068b, moduleTitle=Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58312139068b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294042, encodeId=223c129404256, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, objectType=article, longId=213591, objectId=78a9213591c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78a9213591c8, replyNumber=0, likeNumber=114, createdTime=2021-07-02, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78a9213591c8, moduleTitle=NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78a9213591c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294041, encodeId=e2c7129404147, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, objectType=article, longId=213289, objectId=5cdb21328936, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cdb21328936, replyNumber=0, likeNumber=133, createdTime=2021-06-28, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cdb21328936, moduleTitle=Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cdb21328936)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294040, encodeId=1d5412940404a, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, objectType=article, longId=205766, objectId=c84a205e66fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c84a205e66fd, replyNumber=0, likeNumber=151, createdTime=2021-01-17, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c84a205e66fd, moduleTitle=BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c84a205e66fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294039, encodeId=c2da129403916, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, objectType=article, longId=203520, objectId=4ff9203520a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ff9203520a1, replyNumber=0, likeNumber=59, createdTime=2020-11-20, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ff9203520a1, moduleTitle=NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ff9203520a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294038, encodeId=a223129403819, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖, objectType=article, longId=198242, objectId=909a19824200, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=909a19824200, replyNumber=0, likeNumber=94, createdTime=2020-07-30, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=909a19824200, moduleTitle=Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=909a19824200)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294037, encodeId=66bc129403e2c, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕, objectType=article, longId=194661, objectId=5fd5194661ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5fd5194661ef, replyNumber=0, likeNumber=92, createdTime=2020-05-25, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5fd5194661ef, moduleTitle=JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5fd5194661ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294036, encodeId=a6be129403654, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, objectType=article, longId=191603, objectId=16ab191603bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16ab191603bc, replyNumber=0, likeNumber=79, createdTime=2020-04-08, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16ab191603bc, moduleTitle=欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16ab191603bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294035, encodeId=5760129403523, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病, objectType=article, longId=189905, objectId=801b18990536, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=801b18990536, replyNumber=0, likeNumber=0, createdTime=2020-03-14, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=801b18990536, moduleTitle=FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=801b18990536)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294034, encodeId=53e512940346e, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, objectType=article, longId=188799, objectId=77e1188e9962, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77e1188e9962, replyNumber=0, likeNumber=107, createdTime=2020-02-27, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77e1188e9962, moduleTitle=礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77e1188e9962)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294033, encodeId=2f62129403343, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, objectType=article, longId=187289, objectId=33a518e289cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=33a518e289cb, replyNumber=0, likeNumber=93, createdTime=2020-02-04, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=33a518e289cb, moduleTitle=欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=33a518e289cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294032, encodeId=71d612940323e, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, objectType=article, longId=167983, objectId=85e516e98361, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85e516e98361, replyNumber=0, likeNumber=89, createdTime=2019-06-12, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85e516e98361, moduleTitle=第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85e516e98361)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294031, encodeId=e3d2129403100, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, objectType=article, longId=167970, objectId=f88316e97041, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f88316e97041, replyNumber=0, likeNumber=109, createdTime=2019-06-11, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f88316e97041, moduleTitle=第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f88316e97041)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294030, encodeId=5c3012940305f, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161211, objectId=849816121109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=849816121109, replyNumber=0, likeNumber=130, createdTime=2019-02-28, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=849816121109, moduleTitle=喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=849816121109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294029, encodeId=f44912940295c, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, objectType=article, longId=161199, objectId=4d8e16119952, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4d8e16119952, replyNumber=0, likeNumber=110, createdTime=2019-02-28, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4d8e16119952, moduleTitle=礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4d8e16119952)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294028, encodeId=48cd1294028b1, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？, objectType=article, longId=159719, objectId=117f159e19e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=117f159e19e4, replyNumber=0, likeNumber=101, createdTime=2019-02-11, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=117f159e19e4, moduleTitle=BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=117f159e19e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1294027, encodeId=ed56129402e53, content=<a href='/topic/show?id=bb0e8081b2' target=_blank style='color:#2F92EE;'>#GLP-1受体激动剂#</a>, objectTitle=礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病, objectType=article, longId=149977, objectId=93781499e7e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93781499e7e4, replyNumber=0, likeNumber=79, createdTime=2018-09-30, rootId=0, userName=Eleven11, userId=e183245, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93781499e7e4, moduleTitle=礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93781499e7e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

GLP-1受体激动剂

2020-05-29

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Lancet Diabetes Endocrinol：应用GLP-1受体激动剂治疗2型糖尿病患者的心血管、死亡率和肾脏结局——随机试验的系统回顾和荟萃分析

2021-11-10

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Cardiovasc Diabetol：Meta 分析显示GLP-1受体激动剂对主要心血管事件具有中度获益

2021-09-30

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Lancet Diabetes Endocrinol：GLP-1受体激动剂可降低T2DM患者的多种心血管及肾脏不良事件的发生率

2021-08-26

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Lancet：新型双GIP和GLP-1受体激动剂单药治疗可以显著改善糖尿病血糖和体重水平

2021-07-09

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

NEJM：长效GLP-1受体激动剂Efpeglenatide对糖尿病患者心血管及肾脏结局具有改善作用

2021-07-02

heli0118 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Diabetes Care述评：“明星药”GLP-1受体激动剂对心血管疾病的全面影响

2021-06-28

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

BMJ：SGLT-2抑制剂或GLP-1受体激动剂治疗糖尿病的临床优势

2021-01-17

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

NEJM：GLP-1受体激动剂治疗非酒精性脂肪性肝炎（NASH）：脂肪变性和肝损伤显著减轻，但纤维化改善不明显

2020-11-20

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

Diabetologia：GLP-1受体激动剂lixisenatide降低全胰切除术后糖尿病患者餐后血糖

2020-07-30

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

JCEM：GLP-1受体激动剂治疗肥胖、多囊卵巢综合征和不孕

2020-05-25

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

欧盟批准2型糖尿病药物GLP-1受体激动剂Rybelsus

2020-04-08

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

FDA再次拒绝将Intarcia公司的GLP-1受体激动剂皮下渗透泵ITCA 650，用于治疗2型糖尿病

2020-03-14

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

礼来的GLP-1受体激动剂Trulicity，获得FDA批准用于降低心血管风险

2020-02-27

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

欧洲药品管理局的CHMP支持诺和诺德口服GLP-1受体激动剂Rybelsus，用于治疗2型糖尿病

2020-02-04

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

第79届ADA：与GLP-1受体激动剂相比，Soliqua/Suliqua显著降低了2型糖尿病患者的血糖水平

2019-06-12

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

第79届ADA：双重GIP和GLP-1受体激动剂tirzepatide治疗2型糖尿病的潜力

2019-06-11

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

喜大普奔！降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

礼来降糖新药GLP-1受体激动剂周制剂度易达®（度拉糖肽）正式获批进入中国

2019-02-28

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

BCPT：GLP-1受体激动剂除了降糖，还能护肝，专家怎么看？

2019-02-11

Eleven11 (审核中...)

前往app查看评论内容

#GLP-1受体激动剂#

礼来公司收购Chugai在研口服非肽类GLP-1受体激动剂用于治疗糖尿病

2018-09-30

科室
- - 订阅+
  - 更多科室
工具
服务